Mercury Laboratories Past Earnings Performance
Past criteria checks 2/6
Mercury Laboratories has been growing earnings at an average annual rate of 9.7%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 6.5% per year. Mercury Laboratories's return on equity is 8.6%, and it has net margins of 5.3%.
Key information
9.7%
Earnings growth rate
9.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 6.5% |
| Return on equity | 8.6% |
| Net Margin | 5.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Mercury Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 776 | 41 | 153 | 0 |
| 30 Sep 23 | 767 | 35 | 153 | 0 |
| 30 Jun 23 | 761 | 51 | 145 | 0 |
| 31 Mar 23 | 753 | 56 | 147 | 0 |
| 31 Dec 22 | 692 | 62 | 136 | 0 |
| 30 Sep 22 | 686 | 61 | 140 | 0 |
| 30 Jun 22 | 600 | 39 | 129 | 0 |
| 31 Mar 22 | 579 | 36 | 125 | 0 |
| 31 Dec 21 | 624 | 34 | 121 | 0 |
| 30 Sep 21 | 653 | 49 | 115 | 0 |
| 30 Jun 21 | 708 | 56 | 103 | 0 |
| 31 Mar 21 | 686 | 53 | 108 | 0 |
| 31 Dec 20 | 626 | 43 | 97 | 0 |
| 30 Sep 20 | 596 | 38 | 96 | 0 |
| 30 Jun 20 | 559 | 32 | 93 | 0 |
| 31 Mar 20 | 573 | 32 | 94 | 0 |
| 31 Dec 19 | 576 | 38 | 89 | 0 |
| 30 Sep 19 | 595 | 33 | 86 | 0 |
| 30 Jun 19 | 572 | 30 | 100 | 0 |
| 31 Mar 19 | 555 | 28 | 78 | 0 |
| 31 Dec 18 | 563 | 30 | 77 | 0 |
| 30 Sep 18 | 526 | 33 | 75 | 0 |
| 30 Jun 18 | 543 | 42 | 74 | 0 |
| 31 Mar 18 | 519 | 20 | 73 | 0 |
| 31 Dec 17 | 523 | 22 | 76 | 0 |
| 30 Sep 17 | 490 | 12 | 110 | 0 |
| 30 Jun 17 | 461 | 4 | 74 | 0 |
| 31 Mar 17 | 480 | 27 | 75 | 0 |
| 31 Dec 16 | 450 | 27 | 71 | 0 |
| 30 Sep 16 | 471 | 36 | 72 | 0 |
| 30 Jun 16 | 475 | 38 | 72 | 0 |
| 31 Mar 16 | 477 | 39 | 77 | 0 |
| 31 Dec 15 | 462 | 40 | 71 | 0 |
| 30 Sep 15 | 433 | 35 | 69 | 0 |
| 30 Jun 15 | 434 | 35 | 67 | 0 |
| 31 Mar 15 | 413 | 33 | 64 | 0 |
| 31 Dec 14 | 436 | 29 | 61 | 0 |
| 30 Sep 14 | 439 | 32 | 60 | 0 |
| 30 Jun 14 | 424 | 32 | 59 | 0 |
| 31 Mar 14 | 416 | 32 | 57 | 0 |
| 31 Dec 13 | 385 | 35 | 57 | 0 |
| 30 Sep 13 | 363 | 30 | 56 | 0 |
| 30 Jun 13 | 349 | 26 | 52 | 0 |
Quality Earnings: 538964 has high quality earnings.
Growing Profit Margin: 538964's current net profit margins (5.3%) are lower than last year (8.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 538964's earnings have grown by 9.7% per year over the past 5 years.
Accelerating Growth: 538964's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 538964 had negative earnings growth (-33.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: 538964's Return on Equity (8.6%) is considered low.